| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Novartis Vaccines, Siena, Italy
Aluminum hydroxide (alum) and the oil-in-water emulsion MF59 are widely used, safe and effective adjuvants, yet their mechanism of action is poorly understood. We assessed the effects of alum and MF59 on human immune cells and found that both induce secretion of chemokines, such as CCL2 (MCP-1), CCL3 (MIP-1
), CCL4 (MIP-1β), and CXCL8 (IL-8), all involved in cell recruitment from blood into peripheral tissue. Alum appears to act mainly on macrophages and monocytes, whereas MF59 additionally targets granulocytes. Accordingly, monocytes and granulocytes migrate toward MF59-conditioned culture supernatants. In monocytes, both adjuvants lead to increased endocytosis, enhanced surface expression of MHC class II and CD86, and down-regulation of the monocyte marker CD14, which are all phenotypic changes consistent with a differentiation toward dendritic cells (DCs). When monocyte differentiation into DCs is induced by addition of cytokines, these adjuvants enhanced the acquisition of a mature DC phenotype and lead to an earlier and higher expression of MHC class II and CD86. In addition, MF59 induces further up-regulation of the maturation marker CD83 and the lymph node-homing receptor CCR7 on differentiating monocytes. Alum induces a similar but not identical pattern that clearly differs from the response to LPS. This model suggests a common adjuvant mechanism that is distinct from that mediated by danger signals. We conclude that during vaccination, adjuvants such as MF59 may increase recruitment of immune cells into the injection site, accelerate and enhance monocyte differentiation into DCs, augment Ag uptake, and facilitate migration of DCs into tissue-draining lymph nodes to prime adaptive immune responses.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
1 This work was supported in part by a grant from the European Union (MUVAPRED, Grant no. LSHP-CT-2003-503240).
2 Address correspondence and reprint requests to Dr. Andreas Wack, Department of Molecular Immunology, Novartis Vaccines Research Center, Via Fiorentina 1, 53100 Siena, Italy. E-mail address: andreas.wack{at}novartis.com
3 Abbreviations used in this paper: DC, dendritic cell; iDC, immature DC; alum, aluminum hydroxide.
This article has been cited by other articles:
|
|
 |
|
  M. Wigren, D. Bengtsson, P. Duner, K. Olofsson, H. Bjorkbacka, E. Bengtsson, G. N. Fredrikson, and J. Nilsson Atheroprotective Effects of Alum Are Associated With Capture of Oxidized LDL Antigens and Activation of Regulatory T Cells Circ. Res., June 19, 2009; 104(12): e62 - e70. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Chang, J. A. Hamilton, G. M. Scholz, and C. L. Elsegood Glycolytic control of adjuvant-induced macrophage survival: role of PI3K, MEK1/2, and Bcl-2 J. Leukoc. Biol., June 1, 2009; 85(6): 947 - 956. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Douagi, C. Gujer, C. Sundling, W. C. Adams, A. Smed-Sorensen, R. A. Seder, G. B. Karlsson Hedestam, and K. Lore Human B Cell Responses to TLR Ligands Are Differentially Modulated by Myeloid and Plasmacytoid Dendritic Cells J. Immunol., February 15, 2009; 182(4): 1991 - 2001. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
